FUZAIL HAQ: Open Payments
NPI 1124749155 · WINSTON SALEM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$893 in 70 payments from 14 companies in 2025. Trend: 2023 $53 · 2024 $436 · 2025 $893
Food & beverage: $893
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $333 |
| Novo Nordisk Inc | 13 | $151 |
| PFIZER INC. | 4 | $68 |
| Gilead Sciences, Inc. | 2 | $67 |
| AstraZeneca Pharmaceuticals LP | 4 | $60 |
| Collegium Pharmaceutical, Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $36 |
| Lundbeck LLC | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Novartis Pharmaceuticals Corporation | 1 | $22 |
Products named: VRAYLAR, QULIPTA, Wegovy, UBRELVY, NURTEC ODT, Belbuca, MOUNJARO, REXULTI.
Industry payments across NC — which companies pay providers there.
